Abstract

RadNet, Inc. will report quarterly results after market close on November 9, 2026, and the preview below summarizes consensus expectations, key KPI trajectories, and the latest perspectives from the sell-side on revenue growth, profitability dynamics, and segment trends.

Market Forecast

Consensus for the current quarter points to revenue of 644.63 million US dollars, implying year-over-year growth of 30.38%, with estimated EBIT of 44.18 million US dollars, up 13.44% year over year, and adjusted EPS of 0.21, down 6.01% year over year; no explicit consensus for gross margin or net margin has been published. Based on RadNet’s prior report and commentary, the core services line is expected to continue carrying the topline, with incremental contribution from advanced imaging utilization and ongoing scheduling throughput improvements, while adjusted EPS moderates due to cost investments and mix.

The main business remains centered on services revenue, which continues to scale as volume growth and throughput improvements underpin the topline outlook. The segment with the strongest momentum is advanced imaging, supported by same-center advanced imaging growth of 9.60% year over year alongside continued demand tailwinds; in the most recent quarter, services revenue totaled 592.59 million US dollars.

Last Quarter Review

RadNet, Inc. reported revenue of 622.72 million US dollars, a gross profit margin of 15.20%, GAAP net profit attributable to the parent company of 7.53 million US dollars, a net profit margin of 1.21%, and adjusted EPS of 0.29, a year-over-year change of -6.45%; GAAP net profit rose quarter over quarter by 122.50%. One notable highlight was the revenue delivery above consensus and the maintenance of operating progress despite cost pressures, with management signaling continued momentum through the second half. By business line, services revenue reached 592.59 million US dollars, representing 95.16% of total revenue, while capitation arrangements contributed 30.13 million US dollars; within services, same-center advanced imaging growth was 9.60% year over year.

Current Quarter Outlook

Main business outlook

The core services engine continues to be the central driver of RadNet’s quarterly trajectory. The prior quarter’s services revenue of 592.59 million US dollars demonstrates scale and operating leverage potential when volumes are strong and scheduling throughput is efficient. Into the current quarter, consensus expects total revenue of 644.63 million US dollars, translating to year-over-year growth of 30.38%, with the services line expected to account for the vast majority of the topline.

Margin cadence is a key watch point. Last quarter’s gross margin of 15.20% and net margin of 1.21% reflect both mix and ongoing cost investments, including labor, technology, and physician-related expense. Even as gross margin is not formally guided for the current quarter, the consensus EBIT forecast of 44.18 million US dollars, up 13.44% year over year, implies stable-to-slightly improving operating productivity quarter on quarter if volumes continue to expand and cost inflation remains managed. Adjusted EPS is projected at 0.21, down 6.01% year over year, indicating that while operating profit likely grows, below-the-line items and investment spend may temper per-share earnings in the near term.

Execution in scheduling and capacity remains integral to turning demand into reported revenue. The previous quarter’s outperformance against consensus revenue coincided with healthy same-center trends. A similar pattern this quarter would require sustained throughput gains, continued referral health, and effective payer authorization management. The balance between growth and profitability will be reflected in conversion of volume to revenue and in containment of overtime and contracted services costs, which can expand when demand spikes unexpectedly. For investors tracking sequential performance, GAAP net profit rose sharply quarter over quarter last period, and maintaining a portion of that improvement would support the case for further operating consistency.

Most promising business this quarter

Advanced imaging continues to stand out as the most promising growth vector within services. The reported 9.60% year-over-year same-center growth in advanced imaging volumes underlines demand strength and effective capacity management. This growth is influential because advanced imaging typically carries higher revenue per study, thereby contributing disproportionately to the topline; as a result, even modest sequential gains in these modalities can have a meaningful revenue impact. While the company does not break out advanced imaging revenue separately each quarter, the magnitude of services revenue at 592.59 million US dollars underscores the extent to which advanced imaging supports the overall mix and trend.

This quarter’s growth profile likely remains tied to a combination of referral stability, patient scheduling efficiency, and continued operational initiatives that reduce no-shows and compress authorization turnaround times. Additionally, investments in reading productivity and workflow software can enhance throughput, allowing the organization to process a higher number of studies without linear increases in cost. When converted into EBIT contribution, such throughput gains can offset wage inflation and contracted radiologist costs, anchoring the consensus expectation for a 13.44% year-over-year rise in EBIT to 44.18 million US dollars despite the EPS headwind.

Another important growth lever is the company’s expanding professional services capabilities, enhanced by strategic moves announced recently. While the announced acquisition initiatives are slated for future periods, the related preparation and alignment activities often begin to shape network and workflow advantages early. This can facilitate incremental case capture and improve revenue integrity. Although near-term adjusted EPS is expected to be 0.21, the volume-led revenue growth should provide a supportive base for future operating leverage as these initiatives mature and integrate.

Key stock price drivers this quarter

The first stock-price driver is the revenue print versus consensus, since the market is calibrated around 644.63 million US dollars with year-over-year growth of 30.38%. Upside or downside to this figure will likely be the single most important datapoint for the tape reaction, especially given the operating leverage embedded in the model when volumes surprise. Investors will also watch for the shape of monthly cadence within the quarter, as intra-quarter demand pattern commentary can inform whether run-rate momentum persists into the next period.

The second driver is profitability mix, particularly the relationship between gross margin and operating expenses. Last quarter’s gross margin was 15.20%, and the consensus EBIT of 44.18 million US dollars implies measured operating control. Any signs of cost normalization in contracted services, radiologist coverage, or technology spend could flow through to EBIT and mitigate the -6.01% forecast decline in adjusted EPS. Conversely, if cost pressures remain more persistent than anticipated, the EPS line may hew to consensus even in the presence of a revenue beat, tempering stock reaction.

The third driver involves forward-looking commentary and updates related to professional services expansion and technology-enabled workflow initiatives. Recent announcements about platform expansion and partnerships are relevant to medium-term growth and margin structure, and any commentary on timing, expected integration milestones, or early benefits can shape sentiment. The market will listen for signals on how additional capabilities are expected to be reported and monetized, how these moves influence case capture or reading productivity, and whether management reiterates or refines full-year expectations following the print. This narrative component often influences valuation multiples, especially when revenue growth is already well-telegraphed.

Analyst Opinions

Analyst views collected during the period are predominantly bullish. Barclays maintained a Buy rating with a price target of 79.00 US dollars, citing continued operational momentum and supportive growth drivers. Truist reiterated a Buy rating and increased its price target to 94.00 US dollars, aligning with an overall positive stance across the coverage universe; aggregated sell-side data indicate a Buy average rating and a mean price target of 89.88 US dollars. There were no bearish reports observed in the collected period, pointing to a 100% bullish-to-bearish ratio within our survey window.

The bullish case hinges on three pillars. First, the strong topline trajectory, with consensus revenue at 644.63 million US dollars and year-over-year growth of 30.38%, suggests durable demand that is translating into reported results, reinforced by last quarter’s revenue over-delivery. Second, the EBIT estimate of 44.18 million US dollars, up 13.44% year over year, implies improving operating productivity in tandem with volume growth; analysts view this as evidence that cost control and throughput improvements are taking hold even as the company invests in capabilities. Third, the expected contribution from advanced imaging growth and expanding professional services capability supports a thesis of multi-year revenue expansion and gradual margin enhancement as workflows and capacity scale.

Analysts also recognize the near-term EPS moderation, with consensus adjusted EPS at 0.21, down 6.01% year over year, as a signal of continued investment in people, technology, and professional capacity. In their view, these investments are warranted by the scale benefits apparent in services revenue and by the prospective impact of platform expansion. As a result, they are inclined to emphasize revenue quality and EBIT progression over short-term EPS variability, particularly in quarters where the mix or below-the-line items can create noise.

On balance, the majority outlook across the sell-side community is constructive heading into November 9, 2026. The emphasis is on confirmation of volume-led revenue momentum, stable operating discipline evident in EBIT progression, and clear communication about how emerging initiatives could fold into reported segment performance. Should reported results align with or exceed the 644.63 million US dollars revenue consensus and deliver EBIT broadly consistent with the 44.18 million US dollars expectation, the bullish case anticipates that shares could respond positively to evidence of durable growth and improving operating mechanics.